Huntington and related neurological diseases result from expansion of a polyglutamine (polyQ) tract. The linear lattice model for the structure and binding properties of polyQ proposes that both expanded and normal polyQ tracts in the preaggregation state are random-coil structures but that an expanded polyQ repeat contains a larger number of epitopes recognized by antibodies or other proteins. The crystal structure of polyQ bound to MW1, an antibody against polyQ, reveals that polyQ adopts an extended, coil-like structure. Consistent with the linear lattice model, multimeric MW1 Fvs bind more tightly to longer than to shorter polyQ tracts and, compared with monomeric Fv, bind expanded polyQ repeats with higher apparent affinities. These results suggest a mechanism for the toxicity of expanded polyQ and a strategy to link anti-polyQ compounds to create high-avidity therapeutics.
Huntington and related neurological diseases result from expansion of a polyglutamine (polyQ) tract. The linear lattice model for the structure and binding properties of polyQ proposes that both expanded and normal polyQ tracts in the preaggregation state are random-coil structures but that an expanded polyQ repeat contains a larger number of epitopes recognized by antibodies or other proteins. The crystal structure of polyQ bound to MW1, an antibody against polyQ, reveals that polyQ adopts an extended, coil-like structure. Consistent with the linear lattice model, multimeric MW1 Fvs bind more tightly to longer than to shorter polyQ tracts and, compared with monomeric Fv, bind expanded polyQ repeats with higher apparent affinities. These results suggest a mechanism for the toxicity of expanded polyQ and a strategy to link anti-polyQ compounds to create high-avidity therapeutics.
At least nine inherited neurodegenerative diseases, including Huntington disease, result from an expansion of a polyQ repeat in the relevant disease protein 1, 2 . Huntington disease is an ultimately fatal disease in which affected individuals suffer from a movement disorder, cognitive deficits and psychiatric symptoms. The gene associated with Huntington disease encodes a 348-kDa protein called huntingtin. The first exon of the huntingtin gene (HD exon 1) encodes a polyQ repeat, which in normal individuals contains 35 or fewer glutamine residues. When the number of glutamines exceeds 36, late onset of Huntington disease becomes apparent, with the disease severity and the age of onset correlating with the length of the polyQ tract 1, 2 . Neurodegenerative diseases characterized by polyQ expansions have intranuclear and cytosolic inclusions containing the expanded polyQ protein 3 . Although the role of inclusions in causing neuronal loss is controversial, it is assumed that the pathology of Huntington disease and other polyQ-repeat diseases result from aberrant binding interactions involving expanded polyQ tracts, through inhibition and sequestration of cellular proteins, binding of other polyQ repeats to form insoluble aggregates, or both 4 .
There are several models for the structure of aggregated expanded polyQ, including a b-helical structure 5, 6 and structures with alternating extended segments and turns that pack into a cross-b structure similar to amyloid proteins [7] [8] [9] [10] [11] [12] . The structure of unaggregated polyQ is also of interest, as it can bind, sequester and/or inhibit cellular proteins. Indeed, some cellular proteins, such as the transcriptional activator Sp1, bind soluble mutant huntingtin but not aggregated huntingtin 13 . In addition, soluble polyQ is an alternative target for therapeutic intervention during the lag period that precedes aggregation 14 . Initial models for the structural properties of unaggregated polyQ relied upon data from monoclonal antibodies that preferentially bind expanded polyQ on western blots (1C2 (refs. 15,16) , 1F8 (refs. 17,18) , 3B5H10 (refs. 19,20) , MW1 and MW2 (ref. 21)) or in a biosensor-based assay (1C2 (ref. 22) ). These results were interpreted to indicate that the antibodies specifically recognize a pathologic conformation of soluble expanded polyQ [18] [19] [20] [21] [22] [23] . This model for polyQ structure contributed to a widely accepted structural paradigm for polyQ toxicity, in which long polyQ repeats (436 residues) adopt a different conformation from normal polyQ and the pathological conformation facilitates aggregation and toxic interactions with other proteins [23] [24] [25] . However, studies involving polyQ peptides 14, [26] [27] [28] 49 , and our studies using polyQ tracts in the context of the HD exon 1 protein 29 , demonstrated that the predominant species of both normal and expanded unaggregated polyQ in solution is an extended random coil and showed no evidence for a detectable population of expanded soluble polyQ molecules with global conformational differences from normal polyQ.
To explain the preferential targeting of expanded polyQ tracts by antibodies and other polyQ-binding reagents, we proposed a 'linear lattice' model 29 based upon models for the binding of non-sequencespecific DNA-binding proteins to DNA 30 . In the linear lattice model, polyQ is seen as being composed of repeating binding sites, whose number increases with the length of the polyQ tract; thus, multivalent, but not monovalent, polyQ-binding reagents should effectively discriminate between normal and expanded polyQ repeats. To test the predictions of the linear lattice model and to gain further understanding of the molecular basis for recognition of polyQ by antibodies,we expressed mono-and multivalent versions of the mouse polyQ antibody MW1, solved the crystal structures of the MW1 Fv alone and bound to a polyQ peptide, and compared the binding of monomeric and multimeric MW1 to normal and expanded polyQ tracts in the context of the human HD exon 1 protein. Our results support the predictions of the linear lattice model, in that unaggregated polyQ tracts adopt a random coil-like structure and expanded polyQ tracts contain multiple epitopes for binding anti-polyQ reagents. These findings suggest a strategy for producing covalently linked antipolyQ reagents that bind with high avidity and specificity to expanded polyQ tracts.
RESULTS
The interaction between MW1 and polyQ was studied in the context of three proteins: RNase-10Q, a mutant form of RNase A in which a tenresidue polyQ tract had been introduced 31 ; SUMO-10Q, an analogous form of the small ubiquitin-related modifier protein; and the HD exon 1 protein, which is sufficient to cause a Huntington disease-like phenotype in transgenic mice when it contains an expanded polyQ tract 32 . Genes encoding the MW1 V H and V L domains were isolated from the MW1 hybridoma ( Supplementary Fig. 1 and Supplementary Methods online). A noncovalent MW1 Fv derived from refolding of denatured V H and V L domains expressed in bacteria formed a complex with HD exon 1 fusion proteins containing polyQ tracts, with RNase-10Q and with SUMO-10Q ( Supplementary Fig. 2 online) .
Structures of the MW1 Fv and a polyQ/MW1 Fv complex
The crystal structure of the MW1 Fv, the first structure of a mouse antibody fragment containing a l light chain, was solved by molecular replacement to 2.10-Å resolution. Although the MW1 Fv is a typical immunoglobulin V H -V L heterodimer similar to the more common Vk-containing heterodimers (k light chains are found in B95% of mouse antibodies 33 ) (Fig. 1) , several features distinguish the MW1 Vl domain from Vk domains: a 1-residue deletion in the strand A-A¢ linking region of the MW1 Vl domain results in a smaller kink compared with Vk domains, and extra residues are inserted in the L2 and L3 loops compared with canonical mouse Vk structures ( Supplementary Fig. 1 ).
Attempts to derive an Fab-polyQ or Fv-polyQ structure either by cocrystallization with a polyQ peptide or by soaking Fv crystals in peptide did not result in crystals or did not reveal electron density for a bound peptide, probably owing to low peptide solubility (P.L., data not shown). An alternative strategy to produce a crystallizable Fv-polyQ complex by binding SUMO-10Q, then removing the SUMO protein by protease cleavage, resulted in cocrystals containing a Gly-(Gln) 10 -Gly (GQ 10 G) peptide. Two crystal structures of the MW1 Fv-GQ 10 G complex were solved to 1.68-Å and 2.35-Å resolution, respectively. Electron density maps for both crystal forms revealed well-ordered density for a Q 10 G peptide (Fig. 2a) and similar structures for the six independent copies of the complex (Supplementary Methods).
The GQ 10 G peptide adopts an extended structure about 29 Å long ( Fig. 2 and Table 1 ), which lies in a diagonal groove identified in the structure of the MW1 Fv alone (Fig. 1c) . In a survey of 48 antibodypeptide structures in the Protein Data Bank, the peptide in the MW1-GQ 10 G structure is the most extended and the only one binding diagonally across the combining site ( Table 1 and Supplementary Fig. 3 online) . As a result of the diagonal orientation, the peptide almost completely avoids contact with the H2 and L2 complementarity-determining regions (CDRs). Instead, the six N-terminal glutamine residues of the peptide interact with the L1 and L3 loops of the V L domain, and the four C-terminal glutamines interact with the counterpart loops of the V H domain (Supplementary Structure of the polyQ tract in the MW1 Fv-GQ 10 G complex The overall structure of the Q 10 region of the bound peptide does not correspond to any single secondary or tertiary structural element. Residues Gln2-Gln4, Gln8 and Gln10 (numbered from the first glutamine in the polyQ sequence, as the N-terminal glycine is disordered) have main chain dihedral angles of a polyproline II helix (Supplementary Table 1 ), an extended structure that lacks main chain hydrogen bonds but contains a left-handed helical repeat with 3 residues per turn 34 . Although it has been suggested that the polyproline II structure is stabilized in polyQ tracts by a hydrogen bond between a glutamine side chain and the backbone carbonyl oxygen of the following residue [35] [36] [37] , we found no hydrogen bonds of this type in the GQ 10 G structure. The polyproline II helical structure in the polyQ peptide is interrupted by a short region of b-strand structure involving peptide residues Gln5-Gln7 (Supplementary Table 1 ).
MW1 recognizes polyQ via direct and solvent-mediated hydrogen bonds and van der Waals interactions (Supplementary Table 1 ). The side chains of nine of ten glutamines (all except Gln3) contact the MW1 combining site. Major contacts are provided by the side chains of residues Gln2, Gln4, Gln6 and Gln9; for example, the side chains of peptide residues Gln4, Gln6 and Gln9 form van der Waals contacts in binding pockets involving tyrosine residues of the Fv CDRs (L1 Tyr31, H1 Tyr32 and Tyr33, and H3 Tyr102; a Peptide length is the total number of residues in the bound peptide; residues bound is the number of peptide residues that contact the antibody, defined as containing one or more atoms within 4.0 Å of an atom in the antibody. b Ca-Ca distance (Å ), distance between Ca atoms in the N-and C-terminal antibody-contacting residues of the peptide. 
Structural changes in the MW1 Fv caused by antigen binding
Comparison of the structures of free and complexed MW1 Fv reveals structural rearrangements upon antigen binding (Fig. 1b,c) . Major structural changes involve the H3 loop, in which V H residues 99-102 move to avoid close contact with peptide residue Gln9, and the L3 loop, in which the Ca atom of Lys99 is displaced by B7.6 Å toward the GQ 10 G peptide. The latter rearrangement allows the formation of hydrogen bonds between V L Thr97 and main chain atoms of peptide residues Gln5 and Gln6 (Supplementary Table 1 ). In addition to local rearrangements, the relative orientations of the V H and V L domains differ in the free and complexed Fv structures, so that the V L domains of the free and ligand-bound Fv structures are rotated by about 61 with respect to each other when the V H domains of the two structures are superimposed (Fig. 1b) .
Affinities of mono-and multimeric MW1 Fvs for polyQ
To evaluate the prediction of the linear lattice model that the affinity of anti-polyQ reagents can be markedly increased by multimerization 29 , we compared the binding of monomeric and multimeric versions of the MW1 Fv to RNase-10Q and HD exon 1 proteins containing 16, 25, 39 and 46 glutamines (HD-16Q, HD-25Q, HD-39Q and HD-46Q). For these comparisons, we are interested in macroscopic, or apparent, equilibrium dissociation constants (K d values), which include avidity effects, as opposed to the microscopic K d values (that is, the affinities for binding one Fv to a single polyQ tract) that were derived in our previous study 29 . K d values were obtained by analysis of plots of the equilibrium binding response (R eq ) versus concentration ( Supplementary Fig. 4 online and Table 2 ). Binding data involving the monomeric Fv were fit using a single class of binding sites modeling a 1:1 binding interaction. Binding models yielding macroscopic, or apparent, K d s (models assuming either one or two classes of binding sites) were used to assess the effects of avidity in experiments involving multimeric Fvs.
To establish baseline affinities in the absence of avidity, we first derived the affinities of the monomeric Fv for polyQ tracts. The K d s for binding of the MW1 Fv to tracts of 10, 16, 25, 39 or 46 glutamines (denoted 10Q, 16Q and so on, as above) range from 2.4 to 12 mM ( Table 2) , consistent with previous experiments involving immobilized MW1 Fabs and injected polyQ 29 . The interaction of the MW1 Fv with RNase-10Q (K d ¼ 12 mM) is somewhat lower in affinity than the interactions with the longer polyQ tracts (B3 mM K d s). This result is consistent with the linear lattice model, which predicts that statistical effects result in modest increases in microscopic affinities for a monovalent reagent as the number of potential binding sites increases 29 .
We next compared the binding of dimeric and tetrameric MW1 Fvs to proteins containing normal and expanded polyQ tracts. The experimental conditions were designed to avoid cross-linking of two or more immobilized polyQ proteins by multimeric Fvs, which would obscure potential avidity-related enhancements of the binding of multimeric Fvs to individual polyQ tracts, as follows. (i) The dimeric Fv protein was constructed so that the antigen-combining sites face the same direction, rather than opposite directions as in a domain-swapped diabody 38 .
(ii) The polyQ-containing proteins were immobilized at low coupling densities (B20 response units (RU) and B80 RU). For comparative purposes, we also evaluated binding of the tetrameric Fv under conditions predicted to promote cross-linking (high coupling density, B300 RU; Table 2 ). We conclude that cross-linking of adjacent polyQ tracts by the dimeric Fv at medium coupling density is minimal, because the dimeric Fv-RNase-10Q affinity (K d ¼ 3.2 mM) is similar to the affinities of the monomeric Fv for the 16Q to 46Q polyQ tracts and only slightly higher than the monomeric Fv-RNase-10Q affinity ( Table 2) . To evaluate potential cross-linking by the tetrameric Fv, we compared its binding under conditions that should not promote cross-linking (coupling densities B20 RU and B80 RU) to its binding under conditions predicted to promote cross-linking (coupling density B300 RU). The affinities of the tetrameric Fv for RNase-10Q at the two lower coupling densities are 1.4 and 1.0 mM, about ten-fold higher than the affinity of the monomeric Fv (K d ¼ 12 mM). This affinity increase can be attributed to statistical effects resulting from the presence of four, as opposed to one, combining sites. The tetrahedral distribution of Fvs on the streptavidin tetramer 39 prevents binding of more than one Fv to the 16Q tract; thus, we saw no affinity increase when the tetrameric Fv bound to HD-16Q (K d ¼ 1.1 mM) as compared with its binding to the 10Q tract (K d s ¼ 1.4 and 1.0 mM at low and medium coupling densities, respectively). At high coupling density, we saw a large increase in apparent affinity (K d ¼ 130 nM), resulting from cross-linking of adjacent RNase-10Q molecules by the tetrameric Fv. The observation that the tetrameric Fv-RNase-10Q affinities derived at medium and low coupling densities are similar to each other, and are both weaker than the apparent affinity at high coupling density, suggests that cross-linking of adjacent polyQcontaining proteins is minimal or absent at the medium and low coupling densities.
Having demonstrated that the multimeric Fvs were not crosslinking adjacent polyQ-containing proteins, we can interpret the remaining results as arising from binding interactions between a single immobilized polyQ-containing protein and an Fv. First, we note that the presence of an increased number of glutamines results in tighter Table 2 ). The fact that the latter affinities are only slightly higher than comparable affinities for the dimeric Fv suggests that only two of the four Fvs in the tetrahedrally arranged tetramer are sterically able to bind the polyQ tract at one time. Nonetheless, the consistently greater affinities of the multimeric compared with the monomeric Fvs for the longer polyQ tracts demonstrates that the affinity of an anti-polyQ reagent can be increased through multimerization because the longer polyQ tracts contain multiple binding sites. The finding that two Fvs in the dimeric and tetrameric MW1 constructs are able to simultaneously contact longer polyQ tracts is consistent with an elongated structure for polyQ tracts longer than the (Gln) 10 tract that was crystallized with the MW1 Fv.
DISCUSSION
The linear lattice model explains the enhanced antibody-binding signal observed in the presence of longer polyQ repeats [15] [16] [17] [18] [19] [20] [21] [22] as arising from increased affinity and avidity owing to the repetition of binding epitopes, and it predicts that antibodies should be capable of binding shorter polyQ tracts containing as few as a single binding epitope 29 .
Here we analyze the structure of a short polyQ epitope bound to MW1, one of the antibodies originally reported to be specific for expanded polyQ tracts 21, 40 . The crystal structure of the MW1 Fv-GQ 10 G complex reveals an extended (Gln) 10 tract in which contacts are made between side chain and/or main chain atoms of all ten glutamines and the antibody combining site. The structure of the GQ 10 G peptide bound to the MW1 Fv is consistent with recent computational and NMR studies suggesting that monomeric polyQ has a tendency to adopt a polyproline II helical structure, although not necessarily in contiguous helical stretches 35, 37 . The agreement between the structure of polyQ in the Fv-GQ 10 G crystals and the computational and NMR studies suggests that the polyQ conformation as revealed in the Fv-GQ 10 G crystal structure is representative of structure(s) present in unaggregated soluble polyQ. Consistent with this hypothesis, the structure of free MW1 reveals a diagonal groove in which the extended polyQ peptide binds, thereby inducing rearrangements of the CDR loops. The finding of polyproline II helical structure in the polyQ peptide does not negate the linear lattice model, because the model does not require that polyQ lacks any form of structure. Indeed, double-stranded DNA, which clearly has structure, can be considered a linear lattice 30, 41 . Rather, the point is that in a linear lattice, there are many binding epitopes, whose number increases with the length of the lattice, in contrast to a single discontinuous binding epitope in a globular protein; for example, epitopes recognized by anti-lysozyme HyHEL antibodies 42 or an epitope created by the assumed pathological conformation of expanded polyQ, suggested to be specifically recognized by MW1 and similar anti-polyQ antibodies [18] [19] [20] [21] [22] [23] . Indeed, recent studies suggest that the alternative or pathological conformation adopted by soluble, monomeric polyQ on its pathway to aggregation would be unlikely to elicit antibodies, because it not expected to accumulate as a monomeric species. For example, the pathological conformation of expanded polyQ in an in vitro experiment conducted with 20 mM polyQ is estimated to be only 50 fM 27, 28 . Thus, the soluble preaggregation conformation of polyQ revealed here is likely to be a better target for antibodies or other therapeutic reagents.
Consistent with the linear lattice model, our results show that multivalent Fvs are better suited than monovalent Fv molecules for targeting long, unaggregated polyQ tracts. For example, the tetrameric MW1 Fv binds HD-46Q with a 39-to 52-fold higher apparent affinity than does the monomeric Fv (compare Table 2 ). In addition, the tetrameric Fv binds shorter repeat lengths with lower affinities than longer repeat lengths. Thus, a multivalent reagent with optimal geometry could be capable of discriminating between normal and pathologic polyQ repeats, an essential feature of any reagent to be used in a cellular milieu in which shorter polyQ repeats are present in nondisease proteins. The preference of the tetrameric Fv for binding to expanded polyQ tracts would probably be enhanced in the presence of longer polyQ repeats (as found, for example, in juvenile Huntington disease), which would © 2007 Nature Publishing Group http://www.nature.com/nsmb facilitate trivalent or tetravalent interactions, as opposed to the bivalent interactions inferred from the present results. That is, binding to longer polyQ repeats would be expected to result in even higher apparent affinities and greater discrimination between normal and expanded polyQ than in our experiments, which used tracts containing no more than 46 glutamines. Confirmation of the predictions of the linear lattice mode has direct implications for the pathogenesis of polyQ diseases. Unaggregated expanded polyQ tracts have been implicated in the aberrant recruitment and sequestration of intracellular and nuclear proteins, including transcriptional activators 13, 43 . The linear lattice model provides an explanation for why multivalent cellular proteins, such as transcriptional activators existing as multiprotein complexes, show specificity for expanded polyQ tracts. The lack of a great difference in binding at the (Gln) 36 threshold in our data ( Table 2) should not be interpreted as disproving the biological relevance of the linear lattice model. Instead, it reflects the relatively short (B10 glutamines) epitope size recognized by the MW1 Fv. This short epitope size enhances binding by multimeric Fvs to unexpanded polyQ tracts such as the tract in HD-25Q by allowing more than one antibody combining site to bind. In contrast, a polyQ-interacting protein recognizing a longer polyQ epitope would be expected to better distinguish between unexpanded and expanded polyQ, particularly if it were multimeric. For example, if one neglects potential steric or linking effects, a dimeric polyQ-interacting protein with an epitope size Z18 glutamines would show preferential binding to polyQ containing Z36 glutamines, as would a trimeric protein with an epitope size Z12 glutamines.
For potential therapeutic approaches, the linear lattice model suggests that researchers should covalently link anti-polyQ reagents to form multivalent compounds rather than searching for monomeric inhibitors specific for a pathological conformation of expanded polyQ (as suggested, for example, in ref. 44 ). If they can be delivered to cells, multivalent anti-polyQ proteins may be capable of inhibiting polyQ aggregation or aberrant associations with other proteins. The concept could also be applied to a small-molecule approach: two or more glutamine-specific compounds could be linked together to produce a compound that binds with high avidity and specificity to expanded, unaggregated polyQ repeats.
METHODS
Protein expression. Previous studies involving expression of an MW1 scFv used a nonfunctional k chain pseudogene as the light-chain variable region 40 . We isolated the gene for a correctly rearranged l light chain from the MW1 hybridoma and verified that the V L gene used for our studies corresponds to the protein sequence of purified MW1 Fab ( Supplementary Fig. 1 and Supplementary Methods). PolyQ-containing proteins and monomeric and multimeric versions of the MW1 Fv were produced as described in the Supplementary Methods.
Generation of an MW1 Fv-GQ 10 G complex for crystallization. An MW1 Fv-GQ 10 G complex was generated by proteolytic cleavage of an Fv-SUMO-10Q complex. Purified SUMO-10Q was mixed with a non-His-tagged version of the MW1 Fv at a molar ratio of 5:1. The complex was separated from free SUMO-10Q by gel-filtration chromatography ( Supplementary Fig. 2 ) on a Superdex200 (16/60) column (Amersham Biosciences). To remove the SUMO portion of the fusion protein, 400 units SUMO protease (LifeSensors) was added to 12 ml purified complex (B5 mg ml -1 ) in 20 mM Tris (pH 7.5) and 150 mM NaCl and incubated at 4 1C overnight. Uncleaved complexes and cleaved SUMO proteins were removed from the Fv-GQ 10 G complex using nickel-nitrilotriacetic acid (Ni-NTA) beads. The supernatant was concentrated to B15 mg ml -1 in 20 mM Tris (pH 7.5), 150 mM NaCl and 0.01% (w/v) NaN 3 . The purified Fv-GQ 10 G complex was analyzed by MALDI-TOF MS, which confirmed the presence of the peptide in the sample (data not shown).
Structure determinations and analyses. The structure of the MW1 Fv (space group P2 1 2 1 2 with two Fv molecules in the asymmetric unit) was determined and refined to 2.10 Å (Supplementary Methods). The final model (R free ¼ 25.5%; R cryst ¼ 22.9%) contains V L residues 1-114, V H residues 1-118, three sulfate ions and 299 water molecules in the asymmetric unit ( Table 3) . The structure of the Fv-GQ 10 G complex was solved in space groups P2 1 2 1 2 (two complexes per asymmetric unit) and P2 1 (four complexes per asymmetric unit) ( Table 3) . The final models contain V L residues 1-114, V H residues 1-118, peptide residues Q 10 G (the N-terminal glycine of the peptide is disordered) and 290 and 928 water molecules in the P2 1 2 1 2 and P2 1 asymmetric units, respectively (Table 3) .
Superpositions and comparisons of structures were done with LSQKAB in the CCP4 suite 45 . CNS 46 was used to calculate buried surface areas using a 1.4-Å probe and to identify interacting residues using the following criteria: a distance of o3.5 Å and a hydrogen bond angle of 4901 for hydrogen bonds, and a maximum distance of 4.0 Å for a van der Waals interaction. Shape complementarity indices (Sc) were calculated as described 47 using Sc in the CCP4 suite 45 . Secondary structure analysis of the GQ 10 G peptide was done with PROSS (http://www.roselab.jhu.edu/utils/pross.html) and PROCHECK (http:// www.biochem.ucl.ac.uk/~roman/procheck/procheck.html).
Binding studies. A surface plasmon resonance-based assay using a BIACORE 2000 instrument was used to derive affinities. To avoid complications created by cross-linking of polyQ tracts by two or more immobilized Fvs, we injected Fv constructs over immobilized polyQ-containing proteins. HD exon 1 fusion proteins, RNase10-Q or a mock solution for background subtraction were covalently coupled to CM5 biosensor chips using primary amine chemistry (according to the Biacore manual). Serial dilutions of Fvs were injected at 50 ml min -1 in 20 mM Tris, 150 mM NaCl and 0.005% (v/v) surfactant P20 (pH 7.4), and the reactions were allowed to closely approach or reach equilibrium. Macroscopic, or apparent, equilibrium dissociation constants (K d s), which include avidity effects, were derived by nonlinear regression analysis of plots of the equilibrium binding response, R eq , versus the log of the analyte concentration ( Supplementary Fig. 4 ). Binding data were fit to the least complex empirical model that fit the data well: a two-site binding model (for Fv dimer-HD-16Q, tetramer-HD-39Q and tetramer-HD-46Q interactions; only high affinity K d s are listed in Table 2 ) or a one-site binding model (remaining binding reactions). As we wished to evaluate the effects of multivalent binding on the apparent affinities, we did not model the data with microscopic (stepwise) binding models, because they are defined in terms of monovalent binding events. In the version of this article initially published, the incorrect corresponding authors were listed. The corresponding author should be Pingwei Li (pingwei@neo.tamu.edu). We apologize for this mistake. The citation should appear on page 381, in the eighth sentence of the article's second paragraph, as follows: "However, studies involving polyQ peptides 14, [26] [27] [28] 49 , and our studies using polyQ tracts in the context of the HD exon 1 protein 29 , demonstrated that the predominant species of both normal and expanded unaggregated polyQ in solution is an extended random coil and showed no evidence for a detectable population of expanded soluble polyQ molecules with global conformational differences from normal polyQ."
These errors have been corrected in the HTML and PDF versions of the article.
